Finance News – Zepbound
What is your interest today?
Bitcoin
Crypto
Btc
Ceo
Stocks
Investors
Tariffs
Shares
Stock
Stock Market
Crypto Assets
Cryptocurrency
Ethereum
Price
Markets
Xrp
Stablecoin
Investment
Blockchain
Etf
Bse
Ipo
Eth
Sec
Index
Solana
Trade
Inflation
Earnings
Coinbase
Interest Rates
Revenue
Token
Sensex
Wall Street
China
Nasdaq
Federal Reserve
Nse
Treasury
Traders
Bse Sensex
Gold
Sp 500
Nifty
Economy
Tesla
Usd
Profit
Investor
Policies
Nifty Bank Index
Price Ratio
Media Agencies
User Wallets
Modella
Withholding Taxes
Crypto Index Etfs
Erc 404
Amber Enterprises
Filter by:
- ABC News Business
- BBC Business
- Business Insider Markets
- CBC Business
- City A.M.
- CNBC Business
- CoinDesk
- Cointelegraph
- Crypto News
- CryptoSlate
- Decrypt
- Economic Times Markets
- Euronews Business
- Financial Post Top Stories
- Financial Times
- Finextra Crypto
- Finextra Market
- Finextra Wealth
- Globe and Mail Investing
- Investing.com Global Markets
- Investing.com Global Mkts
- Investopedia
- Kiplinger
- MarketWatch MarketPulse
- MarketWatch Top Stories
- Quartz
- Sky News Money
- Sydney Morning Herald Biz
- Sydney Morning Herald Business
- TechCrunch Fintech
- The Block
- The Guardian – Business
- WSJ Markets News
Quartz • May 12, 2025
Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study
The superior results of Eli Lilly’s medication compared to Novo Nordisk’s in the recent trial may influence market dynamics and investor confidence within the competitive obesity t...
Read Full Article →
CNBC Business • May 01, 2025
Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer...
Eli Lilly experienced a significant increase in sales attributed to strong demand for its weight loss and diabetes medications, yet adjusted its profit forecast following a recent...
Read Full Article →